Investment Portfolio

Wesagen BioTechnologies

Wesagen technology is based on more than a decade of research by Dr. Jack Lawler, Dr. Mustapha Abdelouahed and their team at Harvard University and the Beth Israel Deaconess Medical Center (BIDMC). The technology resulting from Drs. Lawler and Abdelouahed’s research is a platform technology based on the Thrombospondin-1 protein. Wesagen is leveraging this platform technology to develop biologics for oncology and other treatment areas.